MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Rezdiffra is used in adults to treat nonalcoholic steatohepatitis (NASH) in certain situations, along with diet and exercise. NASH involves a buildup of fat in your liver that can cause ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal’s MASH treatment Rezdiffra receives EU approvalAnalyst activity has been notable, with Goldman Sachs reiterating a Buy rating and a $567 price target for Madrigal Pharmaceuticals. Piper ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Rezdiffra’s Market Performance Rezdiffra has demonstrated strong market acceptance since its launch, with prescription rates steadily increasing. According to recent surveys, the drug’s prescription ...

Following the latest nod, Rezdiffra became the first and only therapy to be approved for the treatment of MASH in the European Union (EU). The approval was based on Rezdiffra’s favorable benefit-risk ...